Skip to content

Study · Animal study (in vivo) · mouse · 2025

3 results

AMPK agonist AICAR ameliorates maternal hepatic lipid metabolism disorder, inflammation, and fibrosis caused by PM2.5 exposure during pregnancy.

Wan T, Chen Z, Li J, Yuan X, Zheng M, Qin L, Zhang L, Hou T, Liu C, Li R

Scientific reports13 Mar 2025Cited by 4 (Europe PMC)

PMID40082541 (opens in a new tab)PMCIDPMC11906884 (opens in a new tab)DOI10.1038/s41598-025-93395-6 (opens in a new tab)PepBankPUB-40082541
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In pregnant mice, AICAR alleviated gestational particulate-exposure-induced dyslipidemia.

    In plain wordsIn pregnant mice, AICAR reduced abnormal blood lipids compared with particulate exposure plus saline.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseDyslipidemia
    Study

    mousen: not reported in source

    Pregnant C57BL/6 mice exposed to PM2.5
    Comparator
    PM2.5 plus normal saline
    Outcome group
    Lipids · Liver
    Studied dose
    200 mg/kg∙bw per day · intraperitoneal injection · GD13 to GD17As given in this study (mouse).

    Source sentences

    Summary
    We found that gestational PM2.5 exposure induced dyslipidemia in pregnant mice, which was alleviated by AICAR treatment.
    1 context sentence
    Summary · context
    To test this hypothesis, pregnant C57BL/6 mice were randomly assigned to 4 groups: filtered air (FA) + NS (normal saline), PM2.5+NS, FA + AICAR (acadesine, an AMPK activator), and PM2.5+AICAR.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In pregnant mice, AICAR ameliorated hepatic lipid deposition induced by particulate exposure.

    In plain wordsIn pregnant mice, AICAR reduced liver fat deposits compared with particulate exposure plus saline.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseHepatic lipid deposition
    Study

    mousen: not reported in source

    Pregnant C57BL/6 mice exposed to PM2.5
    Comparator
    PM2.5 plus normal saline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    200 mg/kg∙bw per day · intraperitoneal injection · GD13 to GD17As given in this study (mouse).

    Source sentences

    Summary
    whereas the AICAR treatment ameliorated hepatic lipid deposition and fibrosis induced by the exposure to PM2.5 during pregnancy.
    1 context sentence
    Summary · context
    To test this hypothesis, pregnant C57BL/6 mice were randomly assigned to 4 groups: filtered air (FA) + NS (normal saline), PM2.5+NS, FA + AICAR (acadesine, an AMPK activator), and PM2.5+AICAR.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In pregnant mice, AICAR ameliorated hepatic fibrosis induced by particulate exposure.

    In plain wordsIn pregnant mice, AICAR reduced liver scarring compared with particulate exposure plus saline.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseHepatic fibrosis
    Study

    mousen: not reported in source

    Pregnant C57BL/6 mice exposed to PM2.5
    Comparator
    PM2.5 plus normal saline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    200 mg/kg∙bw per day · intraperitoneal injection · GD13 to GD17As given in this study (mouse).

    Source sentences

    Summary
    whereas the AICAR treatment ameliorated hepatic lipid deposition and fibrosis induced by the exposure to PM2.5 during pregnancy.
    1 context sentence
    Summary · context
    To test this hypothesis, pregnant C57BL/6 mice were randomly assigned to 4 groups: filtered air (FA) + NS (normal saline), PM2.5+NS, FA + AICAR (acadesine, an AMPK activator), and PM2.5+AICAR.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.